Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Alexandra E Harper, Yen T Chen, Stephanie Tancer, Kyla R Rodgers, Amber D Crumb, Whitney A Townsend, Jason S Knight, Susan L Murphy
OBJECTIVE: The objective of this study was to explore what non-pharmacological interventions have been examined for individuals with antiphospholipid syndrome (APS). METHODS: We conducted a systematic literature search of the databases PubMed, Embase, Scopus, Web of Science, CINAHL, and ClinicalTrials.gov from 1983-Feb. 2023. Our scoping review included studies that examined non-pharmacological interventions for individuals with APS using patient-reported outcome measures...
February 2024: Lupus
#22
Nava R Sharma, Sudarshan Gautam, Prabal Kc, Sajog Kansakar, Marlon E Rivera Boadla, Madalasa Pokhrel, Arjun Basnet, Saral Lamichhane
Antiphospholipid syndrome (APLS) and systemic lupus erythematosus (SLE) are rare autoimmune disorders that afflict a small percentage of the global female population. The complexity of these conditions is further exacerbated by their propensity to give rise to recurrent thrombosis and obstetric morbidity, thereby posing intricate challenges for clinicians and patients alike. One of the most concerning aspects of these diseases is the heightened risk they confer for accelerated atherosclerosis, which can ultimately culminate in the development of acute coronary syndrome (ACS)...
November 2023: Curēus
#23
JOURNAL ARTICLE
Yinmei Zhang, Shangjia Jin, Wenmin Tian, Dongxue Shi, Yang Chen, Liyan Cui, Jiajia Zheng
Obstetric antiphospholipid syndrome (OAPS) is a multisystem disorder characterized by thrombosis or recurrent fetal loss. In this study, we aim to explore the pathological mechanism of OAPS. Herein, we carried out data-independent acquisition (DIA) mass spectrometry quantitative proteomic analysis of serum samples from OAPS patients and healthy controls. A set of 93 differentially expressed proteins was identified, including 75 upregulated and 18 downregulated proteins compared with the levels in controls. Those proteins are enriched in KEGG pathways related to autoimmune diseases, allergic diseases, and pathogen infection...
December 4, 2023: Journal of Proteome Research
#24
JOURNAL ARTICLE
Zetao Ding, Haoyu Pan, Zhixia Yang, Chengde Yang, Hui Shi
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs), which can lead to thrombosis and pregnancy complications. Within the diverse range of aPLs, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have gained significance in clinical practice. The detection of aPS/PT has proven valuable in identifying APS patients and stratifying their risk, especially when combined with other aPL tests like lupus anticoagulant (LA) and anti-β2 -glycoprotein I (aβ2 GPI)...
October 12, 2023: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#25
JOURNAL ARTICLE
F A Cheldieva, T M Reshetnyak, A A Shumilova, K S Nurbaeva, M V Cherkasova, A M Lila, E L Nasonov
The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors. To validate GAPSS in a cohort of patients with systemic lupus erythematosus in Russia. 115 patients with SLE were included in the study, including 51 (44%) patients with systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS), 14 (12%) SLE patients with aPL, and 50 (44%) patients with SLE...
August 2023: Doklady. Biochemistry and Biophysics
#26
JOURNAL ARTICLE
T M Reshetnyak, F A Cheldieva, M V Cherkasova, S I Glukhova, A M Lila, E L Nasonov
The role of antiphospholipid antibodies (aPL), which are not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood. The aim of this study was to determine the clinical significance of IgG antibodies for domain 1 of β2 -glycoprotein 1 (β2 -GP1), IgG anti-β2 -GP1DI, in patients with APS with and without SLE. The study included 187 patients with APS with or without SLE, 49 patients formed the comparison group, and 100 apparently healthy individuals formed the control group...
August 2023: Doklady. Biochemistry and Biophysics
#27
JOURNAL ARTICLE
Yin Long, Can Huang, Yixin Cui, Zhijuan Xie, Yangzhong Zhou, Xiaohua Shi, Yijun Song, Xinping Tian, Mengtao Li, Juntao Liu, Xinyan Liu, Xiaofeng Zeng, Jiuliang Zhao
Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis...
October 11, 2023: Clinical and Experimental Medicine
#28
REVIEW
Rencai Qin, Haiqi Wu, Hui Guan, Chun Tang, Zhihua Zheng, Chong Deng, Chengshun Chen, Qinghua Zou, Liwei Lu, Kongyang Ma
Anti-phospholipid autoantibodies are a group of antibodies that can specifically bind to anionic phospholipids and phospholipid protein complexes. Recent studies have reported elevated serum anti-phospholipid autoantibody levels in patients with antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, metabolic disorders, malaria, SARS-CoV-2 infection, obstetric diseases and cardiovascular diseases. However, the underlying mechanisms of anti-phospholipid autoantibodies in disease pathogenesis remain largely unclear...
November 2023: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#29
JOURNAL ARTICLE
Katsuhiko Yoneda, Yo Ueda, Kenji Tanimura, Hisashi Arase, Hideto Yamada, Jun Saegusa
BACKGROUND: β2-glycoprotein I (β2GPI) complexed with human leukocyte antigen DR (β2GPI/HLA-DR) was found to be a major autoantibody target in antiphospholipid syndrome (APS). This study aimed to reveal the association between anti-β2GPI/HLA-DR antibodies and vascular thromboses in women with systemic rheumatic diseases. METHODS: We conducted a retrospective longitudinal study. We measured anti-β2GPI/HLA-DR antibodies and compared them with anti-phospholipid antibody (aPL) profiles and the adjusted global antiphospholipid syndrome score (aGAPSS)...
October 6, 2023: Arthritis Research & Therapy
#30
REVIEW
Juan J Fierro, Manuela Velásquez-Berrío, Alexandra Ospina, Svenja Henning, Karina de Leeuw, Ángela P Cadavid J
Hydroxychloroquine (HCQ) is obtained by hydroxylation of chloroquine (CQ) and the first indication was malaria. Nowadays, HCQ is commonly used in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) with favorable results. Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and/or pregnancy morbidity and persistent positivity of antiphospholipid antibodies. Around 20-30% of pregnant women with APS develop adverse pregnancy outcomes despite conventional treatment with aspirin and heparin, called refractory obstetric APS...
September 23, 2023: Rheumatology International
#31
REVIEW
Z Amoura, B Bader-Meunier, C Bal Dit Sollier, A Belot, Y Benhamou, H Bezanahary, F Cohen, N Costedoat-Chalumeau, L Darnige, L Drouet, E Elefant, A Harroche, M Lambert, T Martin, I Martin-Toutain, A Mathian, A Mekinian, M Pineton De Chambrun, L de Pontual, D Wahl, C Yelnik, S Zuily
Antiphospholipid syndrome (APS) is a chronic autoimmune disease involving vascular thrombosis and/or obstetric morbidity and persistent antibodies to phospholipids or certain phospholipid-associated proteins. It is a rare condition in adults and even rarer in children. The diagnosis of APS can be facilitated by the use of classification criteria based on a combination of clinical and biological features. APS may be rapidly progressive with multiple, often synchronous thromboses, resulting in life-threatening multiple organ failure...
September 19, 2023: La Revue de Médecine Interne
#32
JOURNAL ARTICLE
Gabriel Figueroa-Parra, Jose A Meade-Aguilar, Hannah E Langenfeld, Mariana González-Treviño, Mehmet Hocaoglu, Andrew C Hanson, Larry J Prokop, M Hassan Murad, Rodrigo Cartin-Ceba, Ulrich Specks, Vikas Majithia, Cynthia S Crowson, Alí Duarte-García
BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease clinically associated with thrombotic and obstetric events. Additional manifestations have been associated with APS, like diffuse alveolar hemorrhage (DAH). We aimed to summarize all the evidence available to describe the presenting clinical features, their prognostic factors, and short- and long-term outcomes. METHODS: We performed a mixed-method approach combining a multicenter cohort with a systematic literature review (SLR) of patients with incident APS-associated DAH...
September 16, 2023: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#33
JOURNAL ARTICLE
Hirotaka Matsumi
Impaired implantation is one of the causes of infertility. It occurs under vital inflammatory status due to immune hyperactivation. In the innate immune system, the inflammatory response to pathogenic stimuli is initiated by complement activation. Minimal vasculitis associated with complement consumption in infertile patients may be an underlying mechanism for impaired implantation. Antiphospholipid antibodies regulate the inflammatory response. Recently, a novel autoantibody (neoself antibody) against a complex of β 2-GPI and HLA class II molecules ( β 2-GPI/HLA-DR) has been reported to be an independent autoantibody associated with aPLs...
2023: Obstetrics and Gynecology International
#34
JOURNAL ARTICLE
Kanako Nagaoka, Kayoko Kaneko, Eiko Miyagawa, Sawako Abe, Chie Kohno, Kotoyi Tsurane, Asako Mito, Nobuaki Ozawa, Haruhiko Sago, Naoko Arata, Atsuko Murashima
AIM: Although perinatal thrombotic microangiopathy has become increasingly understood, the racial characteristics of patients with this condition remain unclear. Herein, we report the characteristics of patients with perinatal thrombotic microangiopathy at a single institution in Japan. METHODS: We conducted a retrospective study over a 5-year period from January 1, 2017, to December 31, 2021, using the electronic medical records of pregnant women who delivered at the perinatal center of our hospital...
September 6, 2023: Journal of Obstetrics and Gynaecology Research
#35
REVIEW
Allyssa Hooper, Vanessa Bacal, Mohamed A Bedaiwy
PROBLEM: The current standard prevention of obstetric complications in patients with antiphospholipid antibody syndrome (APS) is the use of combination low-dose aspirin and low molecular weight heparin. However, 20-30% of women still experience refractory obstetrical APS. Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies. The objective of this study was to evaluate the risk of pregnancy loss upon treatment with HCQ among women with refractory obstetrical APS...
September 2023: American Journal of Reproductive Immunology: AJRI
#36
JOURNAL ARTICLE
Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, H Michael Belmont, Maria Laura Bertolaccini, D Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesús, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-García, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K Leaf, Nina Kello, Jason S Knight, Carl Laskin, Alfred I Lee, Kimberly Legault, Steve R Levine, Roger A Levy, Maarten Limper, Michael D Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V Seshan, Savino Sciascia, Maria G Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cécile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan
OBJECTIVE: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. METHODS: This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators' consensus as the gold standard...
October 2023: Annals of the Rheumatic Diseases
#37
JOURNAL ARTICLE
Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, H Michael Belmont, Maria Laura Bertolaccini, D Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesus, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-Garcia, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K Leaf, Nina Kello, Jason S Knight, Carl Laskin, Alfred I Lee, Kimberly Legault, Steve R Levine, Roger A Levy, Maarten Limper, Michael D Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V Seshan, Savino Sciascia, Maria G Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cecile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan
OBJECTIVE: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. METHODS: This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators' consensus as the gold standard...
October 2023: Arthritis & Rheumatology
#38
REVIEW
Stephane Zuily, Ricard Cervera, Thomas Foret, Stefania Bertocchi, Angela Tincani
The antiphospholipid syndrome (APS) is an autoimmune and prothrombotic condition defined by the association of thrombotic events and/or obstetrical complications and the persistence of antiphospholipid antibodies (aPL) over time. Among the new criteria recently included in the 2023 ACR/EULAR classification criteria for APS, thrombocytopenia is one of the most frequent. The occurrence of thrombocytopenia in aPL/APS patients is important to consider because it could predict APS-related clinical events with a 3-fold increased risk for thrombotic events or obstetrical morbidity or all-cause deaths...
August 22, 2023: Autoimmunity Reviews
#39
JOURNAL ARTICLE
Stephen Windisch, Julia Y Ash, William H Frishman
Antiphospholipid syndrome is a rare, autoimmune thrombophilia defined by vascular thrombosis and pregnancy morbidity, in the setting of documented persistent antiphospholipid antibodies including the lupus anticoagulant, anticardiolipin antibodies, or anti-β2 glycoprotein I antibodies. The presence of antiphospholipid antibodies can be completely asymptomatic, or they can lead to clinical manifestations as severe as catastrophic antiphospholipid syndrome, which involves widespread coagulopathy over a very short period of time...
August 21, 2023: Cardiology in Review
#40
REVIEW
Dina Zucchi, Rebecca Fischer-Betz, Chiara Tani
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which frequently affects women of childbearing age. Nowadays, pregnancy is not contraindicated in cases of well-controlled disease activity, but pregnancies are still at higher risk of maternal and fetal complications compared to the general population. During pregnancy and puerperium patients are at risk of disease flare, and obstetric complications are more frequent in cases of active disease at conception/beginning of pregnancy, a history of lupus nephritis, and concomitant presence of antiphospholipid syndrome...
August 16, 2023: Best Practice & Research. Clinical Rheumatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
